Review Article Online Publishing Date: | ||||||||||||
IJMDC. 2024; 8(3): 1030-1039 PCSK9 inhibitors as a new modality for treating dyslipidemia Abdulrahman M. Alanazi, Nawaf A. Sheer, Reema A. Alassaf, Haifaa A. Abuhemid, Turki S. Algannas, Abdulaziz M. Alnayil, Abdulaziz M. Alomar.
|
How to Cite this Article |
Pubmed Style Alanazi AM, Sheer NA, Alassaf RA, Abuhemid HA, Algannas TS, Alnayil AM, Alomar AM. PCSK9 inhibitors as a new modality for treating dyslipidemia. IJMDC. 2024; 8(3): 1030-1039. doi:10.24911/IJMDC.51-1703950354 Web Style Alanazi AM, Sheer NA, Alassaf RA, Abuhemid HA, Algannas TS, Alnayil AM, Alomar AM. PCSK9 inhibitors as a new modality for treating dyslipidemia. https://www.ijmdc.com/?mno=183261 [Access: March 26, 2024]. doi:10.24911/IJMDC.51-1703950354 AMA (American Medical Association) Style Alanazi AM, Sheer NA, Alassaf RA, Abuhemid HA, Algannas TS, Alnayil AM, Alomar AM. PCSK9 inhibitors as a new modality for treating dyslipidemia. IJMDC. 2024; 8(3): 1030-1039. doi:10.24911/IJMDC.51-1703950354 Vancouver/ICMJE Style Alanazi AM, Sheer NA, Alassaf RA, Abuhemid HA, Algannas TS, Alnayil AM, Alomar AM. PCSK9 inhibitors as a new modality for treating dyslipidemia. IJMDC. (2024), [cited March 26, 2024]; 8(3): 1030-1039. doi:10.24911/IJMDC.51-1703950354 Harvard Style Alanazi, A. M., Sheer, . N. A., Alassaf, . R. A., Abuhemid, . H. A., Algannas, . T. S., Alnayil, . A. M. & Alomar, . A. M. (2024) PCSK9 inhibitors as a new modality for treating dyslipidemia. IJMDC, 8 (3), 1030-1039. doi:10.24911/IJMDC.51-1703950354 Turabian Style Alanazi, Abdulrahman M., Nawaf A. Sheer, Reema A. Alassaf, Haifaa A. Abuhemid, Turki S. Algannas, Abdulaziz M. Alnayil, and Abdulaziz M. Alomar. 2024. PCSK9 inhibitors as a new modality for treating dyslipidemia. International Journal of Medicine in Developing Countries, 8 (3), 1030-1039. doi:10.24911/IJMDC.51-1703950354 Chicago Style Alanazi, Abdulrahman M., Nawaf A. Sheer, Reema A. Alassaf, Haifaa A. Abuhemid, Turki S. Algannas, Abdulaziz M. Alnayil, and Abdulaziz M. Alomar. "PCSK9 inhibitors as a new modality for treating dyslipidemia." International Journal of Medicine in Developing Countries 8 (2024), 1030-1039. doi:10.24911/IJMDC.51-1703950354 MLA (The Modern Language Association) Style Alanazi, Abdulrahman M., Nawaf A. Sheer, Reema A. Alassaf, Haifaa A. Abuhemid, Turki S. Algannas, Abdulaziz M. Alnayil, and Abdulaziz M. Alomar. "PCSK9 inhibitors as a new modality for treating dyslipidemia." International Journal of Medicine in Developing Countries 8.3 (2024), 1030-1039. Print. doi:10.24911/IJMDC.51-1703950354 APA (American Psychological Association) Style Alanazi, A. M., Sheer, . N. A., Alassaf, . R. A., Abuhemid, . H. A., Algannas, . T. S., Alnayil, . A. M. & Alomar, . A. M. (2024) PCSK9 inhibitors as a new modality for treating dyslipidemia. International Journal of Medicine in Developing Countries, 8 (3), 1030-1039. doi:10.24911/IJMDC.51-1703950354 |